Macimorelin

Drug Profile

Macimorelin

Alternative Names: AEZS-130; ARD-07; D-87575; EP-01572; EP-1572; JMV-1843; Macimorelin acetate; Macrilen; Solorel

Latest Information Update: 26 May 2017

Price : $50

At a glance

  • Originator AEterna Zentaris Inc
  • Class Amides; Carboxylic acids; Indoles; Oligopeptides; Small molecules
  • Mechanism of Action Ghrelin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Somatotropin deficiency
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Somatotropin deficiency
  • Phase II Cachexia

Most Recent Events

  • 05 Apr 2017 Updated efficacy and adverse event data from a phase III trial in Somatotropin deficiency presented at the 99th Annual Meeting of the Endocrine Society
  • 30 Mar 2017 AEterna Zentaris announces intention to submit NDA to the FDA for Somatotropin deficiency (Diagnosis, In adults) in third quarter of 2017
  • 09 Mar 2017 The Pediatric Committee of the European Medicines Agency agrees to Aeterna Zentaris to postpone its Pediatric Investigation Plan (PIP) until it files an MAA for Macimorelin for the treatment of somatotropin-deficiency in adults
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top